Table 1 Demographic and baseline characteristics of the study participants
Benidipine plus ARB (n=1026) | Benidipine plus BB (n=966) | Benidipine plus TD (n=991) | P-value | |
|---|---|---|---|---|
Demographic | ||||
Sex, male | 520 (50.7%) | 480 (49.7%) | 495 (49.9%) | 0.899 |
Age, years | 63.0±10.6 | 63.3±10.7 | 63.5±10.6 | 0.594 |
Baseline characteristics | ||||
BMI, kg m−2 | 24.7±3.4 | 24.6±3.4 | 24.4±3.4 | 0.209 |
Systolic BP, mm Hg | 153.8±11.8 | 153.6±10.7 | 154.2±12.0 | 0.491 |
Diastolic BP, mm Hg | 89.0±9.7 | 88.5±9.6 | 88.5±9.8 | 0.362 |
Heart rate, beats per min | 74.0±11.1 | 74.3±11.0 | 74.2±11.5 | 0.865 |
Risk factors | ||||
Previous cardiovascular disease | 131 (12.8%) | 110 (11.4%) | 129 (13.0%) | 0.500 |
Previous stroke | 31 (3.0%) | 23 (2.4%) | 23 (2.3%) | 0.546 |
Diabetes | 144 (14.0%) | 137 (14.2%) | 143 (14.4%) | 0.968 |
Dyslipidemia | 400 (39.0%) | 391 (40.5%) | 418 (42.2%) | 0.344 |
Current smoking | 399 (38.9%) | 376 (38.9%) | 390 (39.4%) | 0.972 |
Previous medication | ||||
Antihypertensive agents | 824 (80.3%) | 780 (80.7%) | 803 (81.0%) | 0.919 |
Benidipine | 647 (63.1%) | 620 (64.2%) | 632 (63.8%) | 0.870 |
Other CCB | 120 (11.7%) | 109 (11.3%) | 113 (11.4%) | 0.957 |
ARB | 94 (9.2%) | 93 (9.6%) | 95 (9.6%) | 0.925 |
ACE inhibitor | 17 (1.7%) | 22 (2.3%) | 13 (1.3%) | 0.255 |
BB | 23 (2.2%) | 35 (3.6%) | 33 (3.3%) | 0.165 |
Diuretics | 9 (0.9%) | 8 (0.8%) | 13 (1.3%) | 0.494 |
Concomitant medication | ||||
Anti-platelet agents | 88 (8.6%) | 72 (7.5%) | 77 (7.8%) | 0.631 |
Statin | 174 (17.0%) | 170 (17.6%) | 159 (16.0%) | 0.653 |
Antidiabetic agents | 71 (6.9%) | 68 (7.0%) | 72 (7.3%) | 0.954 |
